Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Travere Therapeutics, Inc. (the "Company") issued a press release announcing certain preliminary financial results for the fourth quarter and year ended December 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this current report.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
  No.       Description

99.1          Press release of Travere Therapeutics, Inc. dated January 9, 2023.


104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



                                            TRAVERE THERAPEUTICS, INC.

Dated: January 9, 2023                      By:      /s/ Elizabeth E. Reed
                                            Name:    Elizabeth E. Reed
                                            Title:   Senior Vice President, General
                                                     Counsel and Secretary

© Edgar Online, source Glimpses